Statement on Relevant Cooperation Matters between Angelalign (Stock Code:06699.HK) and Maxflex

Angelalign Technology Inc. and Shanghai Maxflex Medical Technology Co., Ltd. have established deep‑level cooperation at both capital and business levels. Both parties attach importance to industrial‑chain synergy in upstream raw materials for clear aligners, carry out business deployment leveraging respective industrial resources, and jointly foster the development of China’s domestic invisible orthodontics industry.

On 27 March 2026, Angelalign Technology Inc. (stock code: 06699.HK, hereinafter referred to as “Angelalign”) published its Annual Report for the year ended 31 December 2025. The annual report disclosed two material transactions involving Shanghai Maxflex Medical Technology Co., Ltd. (hereinafter referred to as “the Company”). Relevant explanations in respect of such matters are set out below:

I. Strategic Investment

On 25 August 2025, Wuxi EA, a wholly‑owned subsidiary of Angelalign, entered into an investment agreement with the Company and its then‑existing shareholders (including entities controlled by CareCapital Group, the Angelalign Group and other shareholders of the Company who are independent third‑parties). Pursuant to such agreement, Wuxi EA conditionally agreed to subscribe for 5% of the enlarged registered share capital of the Company at a cash consideration of RMB 10.0 million.

Upon completion of such investment, the Angelalign Group holds a beneficial interest of approximately 9.7% equity in the Company.

II. Product Purchase Cooperation Framework Agreement

On 19 February 2025, Wuxi EA Medical Instruments Technologies Limited, a wholly‑owned subsidiary of Angelalign, entered into a Product Purchase Cooperation Framework Agreement with the Company. Under this agreement, Wuxi EA shall purchase certain raw materials for the manufacture of clear aligners from the Company.

The term of this agreement commences on 19 February 2025 and expires on 31 December 2027. The annual caps for raw‑material purchases by the Angelalign Group from the Company for the years ending 31 December 2025, 2026 and 2027 are RMB 30.0 million, RMB 42.0 million and RMB 58.8 million respectively.

III. Explanations on the Above‑mentioned Matters

The above‑mentioned arrangements reflect Angelalign’s recognition and confidence in the business prospects of the Company, and will further deepen the collaborative cooperation between both parties in the field of raw‑materials and industrial chains for the clear‑aligner industry.

All factual information contained in this statement is sourced from announcements and the 2025 Annual Report publicly released by Angelalign on The Stock Exchange of Hong Kong Limited. For full details, please refer to the official documents published on the HKEXnews website ( https://www.hkexnews.hk ) and the financial reports published by Angelalign ( https://ir.angelalign.com/en/financial-reports/ ).